대한핵의학회지 (The Korean Journal of Nuclear Medicine)

대한핵의학회 (The Korean Society of Nuclear Medicine)
권호 표지

류마티스 관절염환자에서 Tc-99m MIBI 영상의 유용성 평가

Evaluation of Patients with Rheumatoid Arthritis by Tc-99m MIBI Imaging

  • 조인호 (영남대학교병원 핵의학과) ;
  • 천경아 (영남대학교병원 핵의학과) ;
  • 홍영훈 (영남대학교병원 감염.류마티스 내과) ;
  • 이충기 (영남대학교병원 감염.류마티스 내과) ;
  • 하정희 (경북대학교 의과대학 약리학교실)
  • Cho, Ihn-Ho (Department of Nuclear Medicine, Yeungnam University Hospital) ;
  • Chun, Kyung-Ah (Department of Nuclear Medicine, Yeungnam University Hospital) ;
  • Hong, Young-Hoon (Department of Rheumatology, Yeungnam University Hospital) ;
  • Lee, Choong-Ki (Department of Rheumatology, Yeungnam University Hospital) ;
  • Ha, Jeung-Hee (Department of Pharmacology, Kyungpook National University School of Medicine)
  • 발행 : 2004.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적: Tc-99m MIBI 을 이용하여 류마티스관절염의 치료에 대한 약제반응을 알 수 있는지를 조사하였다. 대상 및 방법: Disease modifying antirheumatic drugs(DMARDs) 병합요법으로 치료를 시행하고 3개월 후에 추적관찰이 가능하였던 24명의 류마티스 관절염환자 환자들(여자 15명, 남자 9명, 평균연령: $49{\pm}12$)을 대상으로 하여, 치료 전 적혈구침강속도와 C-반응성단백질의 수치를 조사하고, Tc-99m MIBI 스캔을 얻어서, 치료전후 압통과 부종으로 임상증상의 호전정도를 조사하여 서로 비교하였다. Tc-99m MIBI스캔에서 병적관절의 활막 대 배후 방사능비 (J/B ratio)와 함께 Tc-99m MIBI의 저류율(%R)을 구하였다. 결과: Tc-99m MIBI의 3분, 10분, 180분의 활막 대 배후 방사능비는 혈구침강속도와 C-반응성단백질의 수치와 양의 상관관계를 보여 주었다. 관절의 압통과 부종의 정도를 점수화하여 평가된 임상증상의 호전정도와 3분과 180분사이와 10분과 180분사이의 저류율 각각의 상관계수가 -0.72와 -0.76으로 유의한 음의 상관관계를 나타내었다. 결론: Tc-99m MIBI가 류마티스 관절염의 약제 치료효과평가 및 관절염의 정도를 예측할 수 있는 영상방법의 가능성을 보여 주었지만, 이의 확립을 위해서는 추가적인 연구가 필요할 것으로 사료된다.

Purpose: We investigated whether Tc-99m MIBI imaging is useful to predict the response of drug treatment in patients with rheumatoid arthritis. Materials and Methods: 24 patients (15 women and 9 men, age $49{\pm}12$ year) rheumatoid arthritis and treated with disease modifying antirheumatic drugs (DMARDs) were included in this study. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were measured, and Tc-99m MIBI scan was obtained before drug treatment. Quantitative analysis of uptake in diseased joints was performed and expressed as joint-to background ratio (J/B) and percent retention (%R) of Tc-99m MIBI. Clinical symptoms were evaluated and graded from 0 (no) to 3 (severe) regarding to presence of tenderness and swelling. Results: J/B of the diseased joints were significantly correlated with ESR and CRP (p<0.05). A highly significant correlation was found between the improvement of clinical symptoms and %R of Tc-99m MIBI (p<0.05). Conclusion: The results demonstrate that Tc-99m MIBI scan may be used to predict the therapeutic response in patients with rheumatoid arthritis.

키워드

참고문헌

  1. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10 https://doi.org/10.1016/S0092-8674(00)81109-5
  2. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2000;39:975-81 https://doi.org/10.1093/rheumatology/39.9.975
  3. Morgan C, Lunt M, Brightwell H, Bradburn P, Fallow W, Lay M, et al. Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. Ann Rheum Dis 2003;62:15-9 https://doi.org/10.1136/ard.62.1.15
  4. Dyszlewski M, Blake HM, Dahlheimer JL, Pica CM, Piwnica-Worms D. Characterization of a novel $^{99m}$Tc-carbonyl complex as a functional probe of MDR1 P-glycoprotein transport activity. Mol Imaging 2002;1:24-35 https://doi.org/10.1162/153535002753395680
  5. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistance p-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977-84
  6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24 https://doi.org/10.1002/art.1780310302
  7. Gottesman MM, Fojo T, Bates SE, Multidrug resistance in cancer: role of ATP dependent transporters. Nat Rev Cancer 2002;2:48-58
  8. Higgins CF. The ABC of channel regulation. Cell 1995;82:693-696 https://doi.org/10.1016/0092-8674(95)90465-4
  9. Farrell RJ, Murphy A, Long A, Donnelly S, Cherikuri A, O'Toole D, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000;118:279-88 https://doi.org/10.1016/S0016-5085(00)70210-1
  10. Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. Endocrinol 2003;178:339-46 https://doi.org/10.1677/joe.0.1780339
  11. Montano E, Schmitz M, Blaser K, Simon HU. P-glycoprotein expression in circulating blood leukocytes of patients with steroid-resistant asthma. J Investig Allergol Clin Immunol 1996;6:14-21
  12. Aronica E, Gorter JA, Ramkema M, Redeker S, Ozbas-Gercerer F, van Vliet EA, et al. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 2004;45:441-51 https://doi.org/10.1111/j.0013-9580.2004.57703.x
  13. Jorgensen C, Sun R, Rossi JF, Costes J, Richard D, Bologna C, et al Expression of a multidrug resistance gene in human rheumatoid synovium Reumatol Int 1995;15:83-6
  14. Maillefert JF, Maynadie M, Tebib JG, Aho S, Walker P, Chatard C, et al. Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphcytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisone. Br J Rhemuatol 1996;35:430-5
  15. Yudoh K, Matsuno H, Nakazawa F, Yonezawa T, Kimura T. Increased expression of multidrug resistance of P-glycoprotein of Th1 cells correlates with drug resistance in rheumatoid arthritis. Arthritis Rheum 1999;42:2014-5 https://doi.org/10.1002/1529-0131(199909)42:9<2014::AID-ANR32>3.0.CO;2-R
  16. Llorente L, Richaud-Patin Y, Diaz-Borjon A, Alvarado de la Barrera C, Jakez-Ocampo J, de la Fuente H, et al. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I:Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 2000;67:30-9
  17. Rao VV, Chiu ML, Kronauge JF, Piwnica-Worms D. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J Nucl Med 1994;35:510-5
  18. Chun KA, Lee J, Lee SW, Kang DY, Sohn SK, Lee JK, et al. Effect of multidrug resistance gene-1(mdr1) overexpression in in-vitro uptake of Tc-99m sestaMIBI in murine L1210 leukemia cells. Korean J Nucl Med 1999;33:152-62
  19. Cordobes MD, Starzec A, Delmon-Moingeon L, Blanchot C, Kouyoumdiian J-C, Prevest G, et al. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. J Nucl Med 1996;37:286-9
  20. Kostakoglu L, Kiratli P, Ruacan S, Hayran M, Emri S, Ergun EL, et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med 1998;39:228-34
  21. Del Vecchio S, Ciarmiello A, Pace L, Potena MI, Carriero MV, Mainolfi C, et al. Fractional retention of technetium-99m sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med 1997;38:1348-51
  22. Bom HS, Kim YC, Song HC, Min JJ, Kim JY, Park KO. Technetium- 99m uptake in small cell lung cancer. J Nucl Med 1998;39:91-4